• Price (USD)0.7699
  • Today's Change-0.005 / -0.66%
  • Shares traded112.60k
  • 1 Year change-89.02%
  • Beta--
Data delayed at least 15 minutes, as of Nov 30 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2007
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Organovo Holdings Inc1.58m-11.95m13.16m14.00--0.5262--8.34-1.37-1.370.18112.870.0494----121,307.70-37.46-51.62-39.35-55.48-----757.58-951.91----0.00-----18.7331.96---21.29--
Diffusion Pharmaceuticals Inc0.00-14.99m13.26m16.00--0.5511-----7.50-7.500.0011.790.00----0.00-44.61-57.58-48.21-63.38------------0.00-------49.33------
Graybug Vision Inc0.00-36.88m13.34m27.00--0.3208-----1.72-1.720.001.930.00----0.00-60.45---64.84--------------0.00-------3.17------
Liminal BioSciences Inc296.82k-22.77m13.35m48.00--0.4429--44.97-0.7349-0.28180.00960.97090.004--0.29426,183.66-30.91-69.87-34.74-85.81-----7,818.59-918.04----0.0373---11.19-47.677.88---50.47--
Vyne Therapeutics Inc2.76m-37.75m13.50m28.00--0.3369--4.89-0.675-0.44130.04920.69040.0431--0.523598,678.57-58.89-109.14-75.22-133.5050.27---1,366.41-934.12----0.00---29.7185.3871.31------
Plus Therapeutics Inc73.00k-18.77m13.53m14.00--1.15--185.36-0.8874-0.88740.00340.35010.0031----5,214.29-78.46-50.52-121.32-118.00-----25,715.07-295.80---25.660.3339---100.00---62.59--16.54--
Pulmatrix Inc4.82m-21.85m13.61m24.00--0.3884--2.82-6.84-6.841.489.630.0943--19.87200,791.70-36.50-69.19-41.11-94.91-----387.03-376.68----0.00---59.0943.99-21.03---20.55--
Ibio Inc2.17m-48.92m13.84m105.00--0.2868--6.37-5.60-5.600.24825.370.019--3.4420,685.71-42.84-32.33-52.02-35.4491.90---2,251.43-1,396.73---82.900.323--0.506143.33-114.73--48.82--
Tricida Inc0.00-133.91m13.93m57.00---------2.37-2.370.00-2.440.00----0.00-103.62-66.86-124.10-74.65-----------12.433.30------33.32---16.85--
Malachite Innovations Inc2.19m-1.61m14.06m3.00--5.39--6.43-0.0286-0.02860.03560.03341.02-------75.18---94.57--19.33---73.50-----30.010.3091--------------
Addex Therapeutics Ltd - ADR-100.00bn-100.00bn14.15m----------------------------------------------0.0468--------------
Edesa Biotech Inc0.00-18.42m14.26m16.00--1.20-----1.31-1.310.000.76560.00----0.00-107.04---132.63-------------466.260.00---100.00---109.66---56.66--
Talis Biomedical Corp4.84m-127.13m14.70m242.00--0.0825--3.04-4.64-4.640.17396.650.0161--12.8419,979.34-42.29---49.40---22.01---2,629.45--12.35--0.00---25.10---110.73------
Vincerx Pharma Inc0.00-58.20m14.83m56.00--0.2484-----2.77-2.770.002.820.00----0.00-57.68---69.83--------------0.00-------136.50------
Indaptus Therapeutics Inc0.00-13.88m15.04m70.00--0.5456-----1.68-1.680.003.340.00-------37.36-70.63-42.29-83.20------------0.00------45.42---61.94--
Data as of Nov 30 2022. Currency figures normalised to Addex Therapeutics Ltd's reporting currency: US Dollar USD

Institutional shareholders

3.90%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 30 Sep 2022320.00k2.94%
Renaissance Technologies LLCas of 30 Sep 202229.55k0.27%
FNY Capital Management LPas of 30 Sep 202222.50k0.21%
Millennium Management LLCas of 30 Sep 202219.96k0.18%
Citadel Securities LLCas of 30 Sep 202212.80k0.12%
Two Sigma Securities LLCas of 30 Sep 202212.08k0.11%
UBS Securities LLCas of 30 Sep 20227.03k0.07%
Tower Research Capital LLCas of 30 Sep 2022124.000.00%
Old Mission Capital LLCas of 30 Sep 20220.000.00%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.